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Bipolar disorder is a chronic disease characterized by recurring episodes of mania and depression that can lead to disability. This study 
investigates the protective effects of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a drug with well-known antioxidant properties, 
in a model of mania induced by ketamine in rats. Locomotor activity was assessed in the open-field test. Superoxide dismutase (SOD), 
catalase (CAT) and thiobarbituric acid reactive substances (TBARS) levels were measured in order to evaluate oxidative damage in the rat 
hippocampus and prefrontal cortex. Increased locomotor activity (hyperlocomotion) was observed at the open-field test with ketamine 
treatment (25 mg/kg, i.p., 8 days). Edaravone (18 mg/kg) treatment did not prevent hyperlocomotion in the mania model induced with 
ketamine in rats, but lithium chloride (47.5 mg/kg, i.p., positive control) did prevent hyperlocomotion. Edaravone and lithium chloride 
treatments were found to reduce the increase in SOD and CAT activity following ketamine administration in a non-significant manner but 
caused no change in TBARS levels.
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INTRODUCTION
Bipolar disorder (BD) is a widespread, chronic psychiatric 
disease that leads to disability and that affects 1–4% of the 
general population worldwide (Souza et al. 2014). Although 
the clinical course of BD proceeds with recurring episodes 
of mania and depression and mixed episodes, the most 
significant feature of the disease is the acute manic period 
characterized by euphoria-related rushes of energy, irritable 
mood, increased psychomotor activation, reduced need for 
sleep, impulsivity and psychotic symptoms (Andreazza et al. 
2008, Brüning et al. 2012, Gazal et al. 2014). 
The pathophysiology of BD is difficult to understand due 
to the complex structure of the condition. There have been 
increasing evidence in recent years that oxidative stress plays 
a role in the etiology and progression of neuropsychiatric 
disorders such as BD (Ozcan et al. 2004, Machado-Vieira et al. 
2007, Selek et al. 2008, Brüning et al. 2012, Souza et al. 2014). 
In the event of increased free oxygen radicals and insufficient 
antioxidant capacity, oxidative stress contributes to the 
development of neurodegeneration as a cause of protein, 
DNA and RNA oxidation and lipid peroxidation in various 
cellular layers (Gandhi and Abramov 2012). Clinical studies 
have shown alterations in major antioxidant enzymes and 
increased lipid peroxidation in patients with BD (Kuloglu et 
al. 2002, Ozcan et al. 2004, Machado-Vieira et al. 2007).
Although there have been several studies of drugs with 
known antimanic effects and the identification of additional 
treatments in BD, some patients still do not respond well to 
existing therapies (Brüning et al. 2012). Lithium, the most 
widely used therapy in BD, fails to provide satisfactory 
results in approximately 40% of patients due to insufficient 
response, contraindications and side-effects. Research into 
different drugs tested on animal models is therefore needed 
in the treatment of mania (Price and Heninger 1994).
Edaravone (3-methyl-1-phenyl-2pyrazolin-5-one) is 
a potent free radical scavenger that exhibits antioxidant 
effects by inhibiting hydroxyl radical-dependent and radical-
-independent lipid peroxidation (Otomo et al. 2003, Zhou 
et al. 2013). Edaravone has been shown to have beneficial 
effects on oxidative stress markers including glutathione, 
superoxide dismutase, malondialdehyde and glutathione 
peroxidase (Alhaider 2013). It has been shown to exhibit 
neuroprotective effects against oxidative stress in patients © 
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with cerebral infarction and acute ischemic stroke (Yoshida 
et al. 2006). In vivo and in vitro studies have found that 
edaravone has a neuroprotective effect in animal models 
of amyotrophiclateral sclerosis and Parkinson’s disease 
(Kikuchi et al. 2012). We hypothesized that edaravone, a 
substance with known neuroprotective effects, might have 
protective effects in mania in an animal model of BD.
This study investigated the behavioral and 
neurochemical changes caused by edaravone administration 
in a mania model induced with ketamine in rats.
METHODS
Animals
Forty-eight female Sprague Dawley rats (10–11 weeks 
old; weighing 180–220 gr) were used. Rats were obtained 
from the Karadeniz Technical University Experimental 
Animals Unit. Animals were housed in a quiet room with 
a relative humidity of 50±10%, and a temperature of 22±1°C 
in a 12-hour light-dark cycle with free access to food and 
water. The estrous cycle was evaluated by vaginal smear 
method (Marcondes et al. 2002). Vaginal secretion was taken 
with a plastic pipette with 10 µL of normal saline inserted 
into the rat vagina, but not deeply. The vaginal fluids 
were dropped on glass slides and examined under light 
microscope with 10 and 40× objective lenses. Three types 
of cells were observed: epithelial cells, cornified cells and 
leukocytes. The proportion among them was used for the 
determination of estrous cycle phases. The study protocol 
was approved by Karadeniz Technical University Animal 
Research Local Ethics Committee (Protocol No: 2014/13). 
Drugs and experimental design
The ketamine, edaravone and lithium chloride 
used in the study were obtained from Sigma Chemical 
Company, USA. Lithium chloride was dissolved in saline 
solution (0.9% NaCl) and administered twice a day by the 
intraperitoneal route (i.p.). Edaravone was dissolved in 
1N NaOH, diluted with distilled water, and pH-adjusted 
to 7.4 with 1 N HCL according to the manufacturer’s 
instructions. Edaravone was administered twice a day i.p. 
The doses of lithium, ketamine and edaravone employed 
were selected on the basis of the literature (Ghedim et al. 
2012, Zhou et al. 2013). 
The study groups were designed as follow. Rats were 
administered saline solution, lithium chloride 47.5 mg/kg 
and edaravone 18 mg/kg twice a day i.p. Saline or ketamine 
(25 mg/kg) were administered once a day i.p. from the 8th 
day to the 14th day. Locomotor activities were evaluated 
using the open-field test 30 min after a single injection of 
saline or ketamine on the 15th day (Fig. 1).
Open-field test
The open field procedure is a test used for 
assessment of general activity level, locomotor activity, 
and exploratory behavior. The test apparatus is a 
rectangular structure with a size of 100×100×30 cm3 
(width×length×height). This apparatus is made of a 
white wooden hypethral material evenly divided into 
16 squares. Rats were placed to a predetermined corner 
of the apparatus and observed for 5 min. The whole 
experiment was recorded digitally with the help of a 
camera placed above the test apparatus and the recorded 
images were used for scoring. Within 5 minutes interval, 
the total number of squares crossed with all paws was 
counted and the total distance travelled wasmeasured 
to evaluate their exploratory behavior. The time spent 
in the center of the open field was also measured. In 
addition, the number of central crossings was counted 
to assess the anxiety level of the animals. The apparatus 
was cleaned up with a 10% alcohol solution and dried 
after each individual mouse session.
Fig. 1. Schematic representation of the experimental design.
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Biochemical assay
Homogenization stage
Rats were sacrificed by decapitation. Hippocampus 
(HP) and cortex tissues extracted after decapitation were 
homogenized in 50 mM 1.5 mL Tris-HCl (0.5 mL/L Triton 
X-100) cold buffer solution with a pH of 7.4. Homogenates 
were centrifuged at 3000 rpm at +4°C; 0.5 ml homogenate 
was then mixed with 0.25 mL ethanol-chloroform (in a ratio 
of 2:3) and centrifuged at +4°C at 14,000 g for 60 min. SOD 
measurement was performed in the supernatant obtained. 
CAT and MDA measurement and protein screening were 
performed in supernatant not precipitated with ethanol-
-chloroform.
Tissue malondialdehyde level measurement 
MDA measurement was performed following the 
method described by Mihara and Uchiyama (Mihara and 
Uchiyama 1978). This method involves measurement of the 
color formed by MDA with thiobarbituric acid (TBARS) in 
an acidic environment at an absorbance of 532 nm. 
Superoxide dismutase activity assay 
Superoxide dismutase activity was measured following 
the method described by Sun and Oberley (Sun et al. 1988). 
This is based on spectrophotometric measurement of the 
absorbance of the color resulting from the reduction of 
nitroblue tetrazolium by superoxide radicals produced by 
the xanthine-xanthine oxidase system at 560. Percentage 
inhibition of the reaction catalyzed by SOD was calculated 
based on the decrease occurring in optical density as a result 
of removal of superoxide radicals in the SOD environment. 
The amount of SOD responding to 50% inhibition was 
regarded as one unit.
Catalase assay 
Catalase activity was measured using the 
spectrophotometric Goth (Goth et al. 1991) method. 
Measurement is based on measuring the absorbance of the 
stable yellow complex formed by hydrogen peroxide and 
ammonium molybdate at 405 nm. 
Statistical analysis
The recorded behavioral patterns of the animals 
were viewed offline and scored after the experiment. 
The distance travelled within 5 minutes was measured 
by Tracker 4.92 software program. The normality of the 
data was tested with Shapiro-Wilk test. The non-normally 
distributed data were analyzed using Kruskal-Wallis test 
followed by Mann-Whitney U test. Biochemical data 
were analyzed by one-way analysis of variance (ANOVA) 
followed by Bonferroni or Tamhane post hoc tests when 
appropriate. The study data were expressed as mean 
±standard error. Statistical significance was accepted 
when p<0.05. A power analysis was performed using 
G.POWER 3.0.10 software program. When the effect size is 
0.6, α-error is 0.05, total sample size is 48 and number of 
groups is 6, the power was evaluated as 87% for one-way 
ANOVA test.
RESULTS
Locomotor activity
The study was designed to evaluate the effects of 
edaravone on ketamine induced mania in rats. The 
chronological order of injections and tests is shown in 
a flow diagram (Fig. 1). As presented in Figs 2A and 2C, the 
experimental mania model was successfully established 
with ketamine treatment which induced hyperlocomotion 
in rats evidenced by the significant increase in the number 
of crossings and total distance travelled in the open-field 
test (p<0.05). Edaravone pretreatment (18 mg/kg) did 
not prevent the hyperlocomotion induced by ketamine 
in the open-field test. Lithium chloride pretreatment 
(47.5 mg/kg) significantly reduced the number of crossings 
and total distance travelled in the open-field test (p<0.05). 
The anxiety behaviour measured as the percentage of 
central crossings did not significantly change in ketamine, 
edaravone and lithium treatment groups in comparison to 
control group (Fig. 2B). There was no statisticaly significant 
difference between groups according to the duration of 
central crossings (Fig. 2D).
Measurement of oxidative stress parameters in 
the prefrontal cortex
The oxidative stress parameters in the prefrontal 
cortex (PFC) of rats were measured to evaluate the 
neuroprotective effects of edaravone in a ketamine-
-induced mania model (Table I). Ketamine therapy did 
not result in a significant change in TBARS in the PFC 
compared to the control group (p>0.05). Edaravone 
therapy did not significantly alter TBARS levels in the 
PFC in a ketamine-induced mania model (edaravone 
pretreatment p>0.05). 
The effect of edaravone therapy on the activities of 
the antioxidant enzymes of SOD and CATin the PFC was 
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investigated. Although ketamine increased SOD and 
CAT enzyme activities in the PFC, this increase was not 
statistically significant (p>0.05). Although edaravone 
reduced the increased activities of CAT and SOD, the 
difference did not reach to a statistically significant level 
(edaravone pretreatment p>0.05). 
The effect of lithium chloride, used as a positive 
control, on oxidative stress parameters in the PFC was also 
investigated. The application of lithium in a ketamine-
-induced manic model reduced the increase in CAT and 
SOD activities in a non-significant manner but caused no 
change in TBARS levels (p>0.05).
Fig. 2. The effect of lithium chloride (47.5 mg/kg i.p) on ketamine-induced hyperlocomotion represented by (A) number of square crossings; (B) number of 
center square entries; (C) total distance travalled; (D) duration of center crossing. * denotes p<0.05 as compared to saline/saline group. # denotes p<0.05 
as compared to saline/ketamine group. ¥ denotes p<0.05 as compared to saline/saline group. β denotes p<0.05 as compared to saline/ketamine group.
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Measurement of oxidative stress parameters in 
the hippocampus 
The effect of edaravone therapy on oxidative stress 
parameters in the HP was investigated (Table I). Ketamine 
therapy caused no change in TBARS activity (p>0.05). 
Edaravone pretreatment did not alter TBARS activity in the 
HP in a ketamine-induced manic model (p>0.05). Although 
ketamine caused an increase in CAT and SOD enzyme levels, 
the rise was not statistically significant (p>0.05). Edaravone 
pretreatment did not cause a significant change in CAT 
and SOD levels when compared to saline-ketamine group. 
The effect of lithium chloride pretreatment on oxidative 
stress parameters was assessed in the HP. Lithium chloride 
pretreatment caused no significant change in TBARS levels.
DISCUSSION
Our study shows that the administration of edaravone in 
a ketamine-induced mania model in rats does not prevent 
an increase in locomotor activity, while the application 
of lithium in the positive control group prevents such an 
increase. 
Animal models are used to research pharmacological 
and intracellular mechanisms in psychiatric disorders. 
It is difficult to establish an experimental animal model 
reflecting the complex clinical characteristics of BD (Gazal 
et al. 2014). The principal behavioral model that can be 
assessed in the manic period of BD in experimental studies 
is hyperlocomotion. Ghedim and others (2012) showed 
that hyperlocomotion can be induced with ketamine at 
subanesthetic doses. Ketamine at these doses has also 
been reported to alter oxidative stress parameters in the 
rat brain (Ghedim et al. 2012). Preclinical studies have 
reported that ketamine has an antidepressant effect at 
low doses (5–10 mg/kg). Ketamine at subanesthetic doses 
(10–50 mg/kg) has been shown to lead to hyperlocomotion 
and cellular dysfunction and higher doses have been shown 
to have an anesthetic and dissociative effect (Kato et al. 
2007). An experimental mania model can also be induced 
with substances other than ketamine. Some studies 
have shown that d-amphetamine and ouabain induce a 
hyperlocomotion model specific to mania (Gould et al. 
2001, Wang et al. 2013).
In our study ketamine administered i.p. for 1 week at 
a dose of 25 mg/kg statistically significantly increased the 
total number of squares crossed and the total distance 
travelled in the open-field test. This finding shows that 
an experimental model of hyperlocomotion, a behavioral 
template and marker of the manic period of BD, can 
be induced with ketamine. In addition, the significant 
decrease in hyperlocomotion observed with lithium 
chloride in the positive control group strengthens the 
validity of this model. Edaravone, a potent antioxidant 
drug, was expected to be able to reduce hyperlocomotion 
in the ketamine-induced mania model in the present study. 
However, in contrast to similar studies with antioxidants 
Table I. Effect of pretreatment with edaravone or LiCl on oxidative stress parameters in the prefrontal cortex and hippocampus of rats
Groups TBARS (nmol/mg protein) SOD (units/mg protein) CAT (units/mg protein) 
prefrontal cortex
saline/saline 3059.14±51.67 0.56±0.08 1.17±0.13
ketamin/saline 3180.98±208.28 0.57±0.05 1.40±0.21
edaravone/saline 2894.47±117.30 0.37±0.03 1.20±0.14
edaravone/ketamine 3015.94±192.80 0.38±0.08 0.94±0.13
lithium/saline 3474.60±204.92 0.34±0.02 1.11±0.09
lithium/ketamine 3202.24±223.65 0.46±0.10 0.92±0.08
hippocampus
saline/saline 2718.21±226.54 0.55±0.08 0.56±0.09
ketamin/saline 2743.1±200.11 1.9±0.74 0.77±0.25
edaravone/saline 2880.81±281.57 1.79±0.19 0.65±0.07
edaravone/ketamine 3050.03±236.50 1.67±0.17 0.47±0.09
lithium/saline 3027.24±148.33 1.53±0.62 0.53±0.10
lithium/ketamine 2982.40±134.44 1.06±0.16 0.55±0.05
TBARS: thiobarbituric acid reactive species formation; CAT: catalase; SOD: superoxide dismutase. Data was expressed as mean ±S.E.M (n=6–8 animal per group).
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such as curcumin and melatonin (Gazal et al. 2014, Sauza et 
al. 2014), no significant decrease in hyperlocomotion was 
observed with edaravone. 
Oxidative stress has been shown to play a significant role 
in the pathophysiology of several neuropsychiatric diseases, 
including BD (Amanda et al. 2010). The lower antioxidant 
capacity, high levels of free iron and polyunsaturated fatty 
acid content and higher oxygen consumption of brain 
render it more susceptible to oxidative damage when 
compared to other tissues (Ter-Minassian 2006, Berk et 
al. 2011). Increasing oxygen radicals in tissues can lead to 
neurodegeneration in psychiatric diseases by compromising 
cell membrane transport, signal transmission mechanisms 
and mitochondrial energy production and neuroplasticity 
by leading to lipid peroxidation and protein and nucleic 
acid injury (Mahadik et al. 2001). Experimental studies have 
shown that antioxidant substances have beneficial effects 
on mania by reducing oxidative stress in the PFC and HP 
(Brüning et al. 2012, Gazal et al. 2014, Souza et al. 2014). 
This study also investigated the effects of the antioxidant 
edaravone on antioxidant mechanisms in the rat PFC and HP. 
Edaravone is a potent antioxidant molecule, with 
neuroprotective effects in experimental models of 
Parkinson’s disease and dementia and it has been shown 
to have beneficial effects against oxidative stress in 
experimental models of cerebral ischemia and in clinical 
practice. In the light of these evidence, it is anticipated that 
edaravone might be effective in the treatment of BD, the 
etiology in which oxidative stress has been implicated.
SOD is an enzyme group that reduces superoxide 
anion (O2-) to hydrogen peroxide (H2O2) which is later 
converted into H2O and O2 by the enzyme catalase. In our 
study, levels of SOD and CAT in the rat PFC increased with 
ketamine administration, while the activities of these 
enzymes decreased with edaravone administration, albeit 
not statistically significantly so. The application of lithium 
chloride, used as the positive control, significantly reduced 
hyperlocomotion. The SOD and CAT activities in PFC and 
HP were lower in Lithium chloride-ketamine group when 
compared to those of vehicle-ketamine group but the 
difference was not statistically significant. 
In addition, no variation was observed in this study 
in TBARS levels in the PFC and HP regions with ketamine, 
edaravone and lithium chloride administration. In agreement 
with our results, SOD and CAT activities in the PFC and HP 
in a ketamine-induced experimental schizophrenia model 
have been shown to rise with ketamine administration, 
but the activities of these enzymes decreased with the 
addition of the antioxidant omega-3 (Zugno et al. 2013). 
Another study reported that SOD and CAT activities in the 
PFC and HP in a mania model increased with ouabain and 
that enzyme activities decreased with antioxidant substance 
administration (Brüning et al. 2012). Inconsistent results 
have been reported concerning the effects of antioxidant 
substances on antioxidant enzymes in experimental mania 
models. For example, some studies have reported a rise in 
TBARS levels, and a rise in antioxidant enzyme activities 
and superoxide formation with oxidative stress in the brain 
(Riegel et al. 2009, Brocardo et al. 2010, Jornada et al. 2011, 
Brüning et al. 2012). 
In this study, edaravone used as an antioxidant agent 
exhibited a similar effect to lithium chloride used as the 
positive control, leading to lower levels of SOD and CAT 
enzyme activities in PFC and HP in comparison to saline-
-ketamine treatment group. The result that the lower 
levels did not reach to a statistical significance may be due 
to sample group constitution. The optimal edaravone dose 
in this study was determined referring to previous studies 
in order to prevent side-effects. However, studies involving 
higher doses of edaravone might reveal a more marked 
effect on antioxidant enzymes.
Various biochemical pathways with effects on oxidative 
stress in different psychiatric disorders are not yet fully 
understood. Clinical and experimental studies of oxidative 
stress in BD have reported controversial results. Further 
studies with larger sample size are required in order 
to better elucidate the probable protective effects of 
edaravone in BD. 
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